학술논문
The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years
Document Type
Article
Author
Bazarbachi, Ali; Boumendil, Ariane; Finel, Hervé; Khvedelidze, Irma; Romejko-Jarosinska, Joanna; Tanase, Alina; Akhtar, Saad; Ben Othman, Tarek; Ma’koseh, Mohammad; Afanasyev, Boris; Cheikh, Jean; Briones, Javier; Gülbas, Zafer; Hamladji, Rose-Marie; Elverdi, Tugrul; Blaise, Didier; Martínez, Carmen; Alma, Eleonora; Halaburda, Kazimierz; Sousa, Aida Botelho; Glass, Bertram; Robinson, Steven; Montoto, Silvia; Sureda, Anna
Source
Leukemia; June 2022, Vol. 36 Issue: 6 p1646-1653, 8p
Subject
Language
ISSN
08876924; 14765551
Abstract
Hodgkin lymphoma (HL) patients who relapse after autologous-stem-cell- transplantation (auto-SCT) have traditionally had a poor prognosis. We analyzed 1781 adult HL patients who relapsed between 2006 and 2017 after a first auto-SCT. The 4-year overall survival (OS) after relapse continuously increased from 32% for patients relapsing in 2006–2008, to 63% for patients relapsing in 2015–2017 (p= 0.001). The improvement over time was predominantly noted in patients who had an early relapse (within 12 months) after auto-SCT (p= 0.01). On multivariate analysis, patients who relapsed in more recent years and those with a longer interval from transplant to relapse had a better OS, whereas increasing age, poor performance status, bulky disease, extranodal disease and presence of B symptoms at relapse were associated with a worse OS. Brentuximab vedotin (BV), checkpoint inhibitors (CPI) and second transplant (SCT2; 86% allogeneic) were used in 233, 91 and 330 patients respectively. The 4-year OS from BV, CPI, and SCT2 use was 55%, 48% and 55% respectively. In conclusion, the outcome after post-transplant relapse has improved significantly in recent years, particularly in the case of early relapse. These large-scale real-world data can serve as benchmark for future studies in this setting.